Endpoints News 26. Feb. 2026 Lilly's GLP-1 pill beats Novo’s in diabetes trial, has more side effects
Endpoints News 24. Feb. 2026 Novo Nordisk’s triple-G is competitive with Lilly in obesity, but likely to be second to market
BioPharma Dive 23. Feb. 2026 Novo’s next-gen obesity shot fails to match Lilly drug in head-to-head study
Endpoints News 23. Feb. 2026 Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial
PharmaVoice 12. Feb. 2026 Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift
BioPharma Dive 9. Feb. 2026 Lilly buys ‘in vivo’ CAR-T maker Orna, extending streak of genetic medicine deals
FierceBiotech 9. Feb. 2026 Lilly, Innovent pen $8.8B oncology, immunology collab that 'moves beyond traditional licensing'